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 ABSTRACT1 
 
The gut microbiota is now considered to have a role in regulating the immune 
system and in drug metabolism. Little, however, is known about its role in 
infectious and immunological complications and in metabolism of 
immnosuppressive medications in kidney transplantation. In this pilot study, we 
prospectively collected fecal specimens in 26 kidney transplant recipients and 
characterized the changes in the gut microbiota during the first 3 months after 
kidney transplantation. We utilized 16S rRNA deep sequencing of the V4-V5 
hypervariable region to comprehensively characterize the gut microbiota in the 
fecal specimens. We characterized the changes in the gut microbiota from pre-
transplantation to post-transplantation and we evaluated whether the gut 
microbiota was associated with post-transplant diarrhea, urinary tract infections, 
acute rejection, and tacrolimus dosing requirements. We report a significant 
increase in the phylum, Proteobacteria, from pre-transplantation to post-
transplantation (0.9% vs. 4.1%, respectively, P=0.04, Wilcoxon signed-rank test) 
in the 5 kidney transplant recipients who had available pre-transplant fecal 
specimens. Recipients with post-transplant diarrhea had a lower microbial 
diversity as measured by the Shannon diversity index than those who did not 
develop post-transplant diarrhea (2.5±0.3 vs. 3.4±0.8, respectively, P = 0.02, 
Wilcoxon rank-sum test). Using linear discriminant analysis effect size (LEfSe) 
                                                            
1 Adapted with permission from 1) Lee et al., Gut microbial community structure and 
complications after kidney transplantation: a pilot study. Transplantation 98(7): 697‐705. 
Lippincott Williams & Wilkins. Copyright © 2014 and 2) Lee et al., Gut Microbiota and Tacrolimus 
Dosing in Kidney Transplantation. PLOS ONE 10(3):e0122399. Copyright © 2015.   
 method, we determined that post-transplant diarrhea fecal specimens were 
associated with a significantly lower abundance of Bacteroides, Ruminococcus, 
Coprococcus, and Dorea. 3 kidney transplant recipients developed Enterococcus 
urinary tract infections (UTI) and the 3 fecal specimens associated with 
Enterococcus UTI had a significantly higher median Enterococcus fecal 
abundance than the 23 time-matched fecal specimens from the kidney transplant 
recipients who did not develop Enterococcus UTI (24% vs. 0%, respectively, 
P=0.005, Wilcoxon rank-sum test). The same 3 kidney transplant recipients 
developed acute rejection and the fecal specimens associated with acute 
rejection had a lower abundance of Bacteroidetes (P=0.02, Wilcoxon rank-sum 
test), Clostridiales (P=0.01), and Bacteroidales (P=0.03) and a higher abundance 
of Lactobacillales (P=0.04) than the 23 time-matched fecal specimens from the 
kidney transplant recipients who did not develop acute rejection. In a subset of 
19 kidney transplant recipients who were maintained on tacrolimus and who had 
available fecal specimens in the first week of transplantation, we evaluated 
whether the gut microbiota in the first week of transplantation was associated 
with a dose escalation of tacrolimus at 1 month (Dose Escalation Group, ≥50% 
increase in initial tacrolimus dosing by 1 month, > 6 mg/day) or with no dose 
escalation (Dose Stable Group, <50% increase in initial tacrolimus dosing by 1 
month, ≤ 6 mg/day). The fecal abundance of Faecalibacterium prausnitzii was 
significantly higher in the Dose Escalation Group (N=5) than in the Dose Stable 
Group (N=14) (11.8% vs. 0.8%, P=0.002, Wilcoxon rank-sum test). There was a 
positive linear correlation between the fecal abundance of Faecalibacerium 
 prausnitzii at week 1 post-transplantation and future 1 month tacrolimus dosing 
(R=0.57, P=0.01). In this pilot study, we report one of the first characterizations of 
the gut microbiota after kidney transplantation and we report novel associations 
with post-transplant diarrhea, Enterococcus UTI, acute rejection, and tacrolimus 
dosing requirements in kidney transplantation. 
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CHAPTER 1 
Introduction1 
  
The human gut harbors trillions of bacteria and identification of these bacteria 
has recently been enabled by high-throughput sequencing technologies. In 
particular, 16S rRNA deep sequencing of bacterial DNA allows for a non-invasive 
comprehensive identification of the bacteria in fecal specimens [1]. Based on 
advances in sequencing technologies, the NIH sponsored the Human 
Microbiome Project to better characterize the microbiome in adults lacking 
evidence of disease [2]. In this study, 242 participants provided specimens from 
over 15 different sites on the body including fecal specimens. With regards to the 
fecal microbiota, there was high variation in terms of community membership 
between individual participants and the most common bacteria phyla included 
Bacteroidetes and Firmicutes [2]. The Human Microbiome Project’s main focus 
was to characterize the microbiota in “healthy” individuals lacking disease. 
Recent studies have now indicated a role of the gut microbiota in several disease 
states [3]. 
 
The gut microbiome has been implicated in having a role in infectious 
complications. Clostridium difficile is a recognized well bacterium that causes 
severe diarrhea with the major risk factor for its development being prior 
                                                            
1 Adapted with permission from 1) Lee et al., Gut microbial community structure and 
complications after kidney transplantation: a pilot study. Transplantation 98(7): 697‐705. 
Lippincott Williams & Wilkins. Copyright © 2014 and 2) Lee et al., Gut Microbiota and Tacrolimus 
Dosing in Kidney Transplantation. PLOS ONE 10(3):e0122399. Copyright © 2015.   
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antibiotic use [4]. Antibiotics have the ability to disrupt the microbiota [5] and 
allow for colonization by opportunistic organisms like C. difficile. The importance 
of commensal bacteria in C. difficile infections is demonstrated in a recent study 
utilizing fecal transplantation as a potential treatment for Clostridium difficile [6]. 
In a randomized controlled trial for treating recurrent C. difficile, treatment with 
duodenal infection of donor feces was found to be superior to treatment with 
antibiotics [6]. While the importance of commensal bacteria in the development of 
C. difficile infections is well known, the link between the gut microbiota and the 
risk for development of other pathogenic infections is not well established. In an 
allogeneic bone marrow transplant population, Enterococcus abundance in fecal 
specimens as measured by 16S rRNA deep sequencing preceded development 
of Enterococcus bacteremia in 2 recipients [7]. A follow up study of 94 allogeneic 
bone marrow transplant recipients revealed that Enterococcus domination in the 
stool (defined by ≥30 percent relative abundance) was associated with a 9 fold 
increased risk for Enterococcus bacteremia and that Proteobacteria domination 
in the stool was associated with a 5 fold increased risk for Proteobacteria 
bacteremia [8].  
 
In addition to the gut microbiota’s association with pathogenic infectious 
complications, the gut microbiota has also been implicated in having a role in 
regulating the immune system. Several studies have indicated that certain gut 
bacteria can induce certain lineages of T lymphocytes [9]. Colonization of the 
small intestine of mice with segmented filamentous bacterium has been shown to 
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lead to the induction of Th17 cells [9]. A further study revealed that introduction of 
segmented filamentous bacterium can induce Th17 cells and production of auto-
antibodies, leading to exacerbation of autoimmune arthritis in a mouse model 
[10]. In terms of transplant immunology, little is known about the effects of the gut 
microbiota on allograft rejection. One study of 19 small bowel transplant 
recipients reported an association between a specific gut microbial profile and 
acute rejection of small bowel transplant recipients [11]. Another study reported 
the association between gut microbiota and graft-versus-host disease, a form of 
rejection in allogeneic bone marrow transplantation, specifically that microbial 
chaos measured in fecal specimens was a potential risk factor for development 
of graft-versus-host disease [12]. 
 
The gut microbiota’s potential role in health goes beyond immunological and 
infectious complications and is also implicated in direct and indirect drug 
metabolism. Several drugs are well known to be activated in the intestines to 
produce therapeutic effects such as sulfasalazine, a drug that requires microbial 
azoreductases to transform itself into 5-aminosalicyclic acid and sulfapyridine 
[13]. Recently, digoxin, a common anti-arrythymic drug, has been associated with 
direction inactivation by a common bacteria called Eggerthella lenta [14]. Indirect 
influence on drug metabolism has also been attributed to a gut microbial product 
called p-cresol and acetaminophen. In this study, levels of urinary p-cresol was 
associated with low urinary ratios of acetaminophen sulfate to acetaminophen 
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glucuronide, suggesting competition of O-sulfonation of p-cresol and reduced 
ability to sulfonate acetaminophen [15].  
 
In kidney transplantation, the role that the gut microbiota plays in infectious and 
immunological complications and in drug metabolism has not been well defined. 
This is particularly important since kidney transplant recipients have an increased 
risk for infectious complications given that they are immunocompromised 
patients. Furthermore, immunosuppression is the staple for suppressing allograft 
rejection. Despite mainstay immunosuppressive therapies, allograft rejections still 
occur and the potential contribution by gut microbiota in this process has not 
been well characterized. Potentially influencing allograft rejection is also 
adequate doses of immunosuppressive medications like tacrolimus. Although no 
direct evidence on the gut microbiota’s role in tacrolimus metabolism has been 
established, indirect evidence includes fluctuations in levels of tacrolimus trough 
levels in the settting of diarrhea [16-18] and antibiotics [19, 20]. While some 
studies have proposed downregulation of CYP3A4 and P-glycoprotein in the 
intestinal cells in the setting of diarrhea [16], the role that the gut microbiota may 
have on this process has not been explored. 
 
Little is known about the changes in the gut microbiota after kidney 
transplantation and its relationship to post-transplant complications. One study by 
Fricke et al. investigated the rectal microbiota after kidney transplantation [21]. In 
this study of 60 kidney transplant recipients, urine, blood, and rectal swabs were 
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taken pre-transplantation, 1 month, and 6 months and 16S rRNA deep 
sequencing of each specimen allowed for microbial characterization in each 
specimen. The authors reported significant changes in the rectal microbiota after 
kidney transplantation but did not relate them to specific post-transplant 
complications [21].  
 
In the current study, we conducted a pilot study of characterizing the serial gut 
microbiota in 26 kidney transplant recipients during the first 3 months of kidney 
transplantation. We report the changes in the gut microbiota after kidney 
transplantation and its relationship to post-transplant diarrhea, Enterococcus 
urinary tract infections (UTI), and acute rejection (AR) [22]. In a subset of 19 
kidney transplant recipients, we further report a relationship between a bacterium 
called Faecalibacterium prausnitzii and tacrolimus dosing requirements in kidney 
transplantation [23]. 
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CHAPTER 2 
Methods2 
 
Introduction 
In this pilot study, we prospectively recruited kidney transplant recipients at the 
New York Presbyterian Hospital – Weill Cornell Medical Center into serial fecal 
specimen collections and we characterized the microbiota in the fecal specimens 
using 16S rRNA deep sequencing. From the medical records, we collected post-
transplant complications and tacrolimus dosing and trough levels and we tested 
whether the gut microbiota are associated with post-transplant diarrhea, 
Enterococcus UTI, acute rejection, and tacrolimus dosing requirements. 
 
Study Cohort and Recruitment 
The Institutional Review Board at Weill Cornell Medical College approved the 
study protocol (IRB: 1206012506; “Characterization of Intestinal Microbiota to 
Evaluate Kidney Allograft Status”). All subjects provided written informed consent 
prior to enrolling into the protocol and providing serial fecal specimens. Between 
August 2012 and January 2013, we recruited 26 kidney transplant recipients (24 
kidney transplant recipients and 2 kidney-pancreas transplant recipients) into 
serial fecal specimen collections. Each transplant recipient provided at least two 
fecal specimens within the first 3 months of transplantation.  
                                                            
2 Adapted with permission from 1) Lee et al., Gut microbial community structure and 
complications after kidney transplantation: a pilot study. Transplantation 98(7): 697‐705. 
Lippincott Williams & Wilkins. Copyright © 2014 and 2) Lee et al., Gut Microbiota and Tacrolimus 
Dosing in Kidney Transplantation. PLOS ONE 10(3):e0122399. Copyright © 2015.   
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Kidney Transplant Protocol 
Subjects in the protocol received either a kidney alone transplantation or a 
combined kidney pancreas transplantation. Induction immunosuppressive 
therapy consisted of either anti-thymocyte globulin therapy or basiliximab therapy 
with maintenance oral immunosuppressive therapy consisting of tacrolimus and 
mycophenolate with or without prednisone. Cefazolin, vancomycin, 
ampicillin/sulbactam, or ampicillin/sulbactam/cefoxitin was given as pre-operative 
surgical antibiotic prophylaxis while trimethoprim/sulfamethoxazole, dapsone, or 
atovaquone was given as Pneumocystis jiroveci prophylaxis. The transplant 
recipients also received acyclovir or valgancyclovir for 6 months for 
cytomegalovirus prophlaxis and clotrimazole for 3 months for thrush prophylaxis. 
Demographics and pre-transplant, peri-transplant, and post-transplant clinical 
information were obtained from the electronic medical records of all of the 
subjects. 
 
Collection of Fecal Specimens and DNA Isolation 
Subjects were instructed to collect fecal specimens every 2 weeks after 
transplantation during the first month and once a month in the second and third 
post-transplantation months. The subjects self-collected fecal specimens and the 
fecal specimens were stored at -80°C. DNA from each fecal specimen was 
extracted using a phenol-chloroform bead-beater disruption method as described 
in Ubeda et al. [7]. 
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16S rRNA Variable Region PCR Amplification 
In each specimen, the V4-V5 variable region of the 16S rRNA gene was 
amplified using duplicate 50-μL PCR reactions: 50 ng of purified DNA, 0.2 mM 
dNTPs, 2.5μL of 10X PCR buffer, 1.5 mM MgCl2, 1.25 U Platinum Taq DNA 
polymerase, and 0.2 μM of forward primer ( 563F [5’-nnnnnnnn-
NNNNNNNNNNNN-AYTGGGYDTAAAGNG-3’] and reverse primer (926R [5’-
nnnnnnnn-NNNNNNNNNNNN-CCGTCAATTYHTTTRAGT-3’]). The primers 
possess a 12 base barcode for sample identification and 1-8 additional 
nucleotides preceding the barcode which offset the sequencing of the primers 
[24]. The PCR reaction was run with the following cycling conditions: 1) 94°C for 
3 minutes; 2) 27 cycles of 94°C for 50 seconds, 51°C for 30 seconds, and 72°C 
for 1 minute; 3) 72°C for 5 min. The PCR products were purified using the 
Qiagen PCR purification kit.  
 
16S rRNA Deep Sequencing 
Quantity measurements of the DNA were performed using Agilent Bioanalyzer. 
Illumina adaptors and barcodes were added using the Illumina TruSeq Sample 
Preparation Kit. The resulting PCR products were sequenced on an Illumina 
Miseq Instrument (250 by 250 base pair). 
 
Bioinformatics Analysis 
Sequences were processed using mothur version 1.31.1 [25]. Sequences were 
excluded if they were longer than 400 base pairs, had no exact match to the 
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primer with up to 3 mismatches, had homopolymer stretches longer than 8 base 
pairs, had sequences containing undetermined bases, or did not align to the V4-
V5 variable region of the 16S rRNA variable region. The sequences were aligned 
to the V4-V5 region (SILVA reference) [26] using mothur through the Needleman-
Wunsch algorithm and the sequences were screened for chimeras using Uchime 
and were removed if deemed chimeras [27]. The sequences were clustered 
using the function, pre.cluster, which reduces the effects of sequencing errors in 
overestimating microbial diversity [28]. Sequences were grouped into operational 
taxonomic units (average neighbor algorithm) and were further arranged on the 
basis of 97 percent or greater similarity. Phylogenetic classification (to determine 
the bacteria at the species level) was done with the Bayesian classifier algorithm 
using a bootstrap cutoff of 60% [29].  
 
Post-Transplant Complications 
Post-transplant diarrhea was characterized by a subjective complaint of diarrhea 
and 3 or more bowel movements for 2 or more consecutive days. Urinary tract 
infection was characterized as a positive urine culture (≥50,000 colony forming 
units/mL). Acute rejection was characterized by a biopsy proven allograft biopsy 
that was classified by the Banff criteria [30]. 
 
Dose Escalation and Dose Stable Tacrolimus Group Definitions 
At our kidney transplant center, kidney transplant recipients are routinely given 4 
mg/day of oral tacrolimus in two divided doses unless clinically relevant drug 
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interactions were present. Tacrolimus dosing in each transplant recipient was 
adjusted during the first month of transplantation to maintain a target level of 8 to 
10 ng/mL. These changes were based on tacrolimus trough levels which were 
measured approximately twice a week during the first month of transplantation. 
Tacrolimus levels were measured at New York Presbyterian Hospital – Weill 
Cornell Medical Center’s clinical laboratory services using the platform of a liquid 
chromatography tandem mass spectrometry.  
 
Subjects were characterized into tacrolimus groups based on post-transplant day 
28: Dose Escalation Group (subjects requiring a 50% increase from the standard 
initial tacrolimus dosing) (day 28 tacrolimus dosage > 6 mg/day) and Dose Stable 
Group (subjects not requiring the 50% increase from the standard initial 
tacrolimus dosing) (day 28 tacrolimus dosage ≤ 6 mg/day).  
 
Statistical Analyses 
Alpha diversity (Shannon Diversity Index) was measured using the mothur 
program [25]. A phylogenetic tree was constructed based on the 16S rRNA 
sequence alignment with the program, clearcut, in mothur [25, 31]. Unweighted 
unifrac was calculated using the constructed tree and principal coordinate 
analysis was calculated using the resulting distance matrix [32].  
 
Fisher’s exact test was used to compare groups with dichotomous variables. 
Wilcoxon signed rank test was used to compare paired groups with continuous 
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variables and Wilcoxon rank sum test was used to compare unpaired groups with 
continuous variables. Values that were measured in two groups over time were 
compared using a two-way between-group ANOVA using contrasts. The linear 
discriminant analysis effect size (LEfSe) method was utilized to compare 
significant differences at different taxonomic levels between selected groups [33]. 
Correlations between two continuous variables were evaluated using a Pearson’s 
correlation and univariate linear regressions were calculated between the two 
continuous variables. For any log transformed values, a 0 value was assigned 
the value of half of the lowest value in the series. Variables that were significantly 
correlated (P<0.10) were computed in a multivariable linear regression model. 
Statistical analyses were performed using R 3.1.1 or STAT 12.1 I/C (Statacorp, 
College Station, TX). 
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CHAPTER 3 
Gut Microbiota and Post-Transplant Complications3 
 
Kidney Transplant Cohort Characteristics 
From August 2012 to January 2013, we recruited 26 kidney transplant recipients 
to provide serial fecal specimens. Table 1 provides a summary of the pre-
transplant and peri-transplant characteristics of the patients. We obtained 85 
fecal specimens from the 26 subjects. 
 
Fecal Microbiota Characterization 
DNA was isolated from each of the 85 fecal specimens and was amplified at the 
16S rRNA variable region and sequenced on an Illumina MiSeq as described in 
Chapter 2. We obtained a total of 1,946,273 high quality 16S rRNA sequences. 
For subsequent analysis, a maximum of 5000 reads per specimen were 
randomly selected and the results are based upon 4764±777 reads per fecal 
specimen. 
                                                            
3 Adapted with permission from 1) Lee et al., Gut microbial community structure and 
complications after kidney transplantation: a pilot study. Transplantation 98(7): 697‐705. 
Lippincott Williams & Wilkins. Copyright © 2014 and 2) Lee et al., Gut Microbiota and Tacrolimus 
Dosing in Kidney Transplantation. PLOS ONE 10(3):e0122399. Copyright © 2015.   
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Table 1. Clinical Characteristics of the Study Cohort  
Transplant Recipients, N (%) 26 (100) 
  
General Characteristics  
Age (Median, Interquartile Range) 56, 46-63 
Female, N (%) 13 (50) 
Race  
  Caucasian, N (%) 16 (61.5) 
  Hispanic, N (%) 6 (23.1) 
  African American, N (%) 4 (15.4) 
Organ Type   
  Kidney, N (%) 24 (92) 
  Simultaneous Pancreas & Kidney, N (%) 2 (8) 
Type of Transplantation  
  Living Donor Transplantation, N (%) 14 (53.8) 
  Deceased Donor Transplantation, N (%) 12 (46.2) 
  
Immunosuppressive Therapy  
Induction Antibody Therapy  
   Anti-thymocyte globulin, N (%) 20 (77) 
   Basiliximab, N (%) 6 (23) 
Maintenance Immunosuppressive Drugs  
   Tacrolimus and Mycophenolate Acid, N (%) 25 (96) 
   Tacrolimus and Mycophenolate Mofetil, N (%) 1 (4) 
Steroid Protocol  
   Steroid Maintenance, N (%) 10 (38) 
   Steroid Free, N (%) 16 (62) 
  
Perioperative Antibiotics  
Preoperative Surgical Prophylaxis  
   Cefazolin, N (%) 21 (81) 
   Vancomycin, N (%) 3 (11) 
   Ampicillin/Sulbactam/Cefoxitin, N (%) 1 (4) 
   Ampicillin/Sulbactam, N (%) 1 (4) 
Pneumocystic Jiroveci Prophylaxis  
   Trimethoprim/Sulfamethoxazole, N (%) 23 (88) 
   Dapsone, N (%) 2 (8) 
   Atovaquone, N (%) 1 (4) 
 
From Lee et al., Gut microbial community structure and complications after 
kidney transplantation: a pilot study. Transplantation 98(7): 697-705. Lippincott 
Williams & Wilkins. Copyright © 2014. Reprinted with permission. 
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Changes in Gut Microbiota After Kidney Transplantation 
5 of the 26 kidney transplant recipients provided fecal specimens prior to kidney 
transplantation. These 5 recipients all received the same induction therapy (anti-
thymocyte globulin), Pneumocystis jiroveci pneumonia prophylaxis 
(trimethoprim/sulfamethoxazole), and preoperative surgical antibiotic prophylaxis 
(cefazolin). All of the kidney transplant recipients had not initiated induction 
therapy or preoperative antibiotics prophylaxis prior to providing the pre-
transplant fecal specimens and all provided a two week post-transplant fecal 
specimens.  
 
Figure 1 shows the changes in the gut microbiota in the 5 patients after kidney 
transplantation (Figure 1A – genus level; Figure 1B – phylum level; Figure 1C – 
order level). At the phylum level, the fecal abundance of Proteobacteria 
increased from 0.9% (pre-transplant) to 4.1% (2 week post-transplant) (P=0.04, 
Wilcoxon signed-rank test) (Figure 1B). At the order level, the fecal abundance of 
Enterobacteriales increased from 0.4% (pre-transplant) to 3.9% (2 week post-
transplant) (P=0.04) and the fecal abundance of Erysipelotrichales increased 
from 5.6% to 10.2% (P=0.04) (Figure 1C) (Table 2). 
15 
           
 
Figure 1: Alterations in the Gut Microbiota Following Kidney 
Transplantation. Each of the 5 kidney transplant recipients provided a fecal 
specimen prior to transplantation and prior to receiving any induction 
immunosuppression therapy or antibiotic prophylaxis and a second fecal 
specimen approximately 2 weeks after transplantation. All 5 recipients received 
similar induction therapy, preoperative antibiotics, and PCP prophylaxis therapy. 
The 5 sets of bar graphs show the gut microbiota of the 5 kidney transplant 
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recipients at the genus level over time (Panel A). Each bar represents the relative 
composition of bacteria in the stool sample from each patient. The x-axis 
indicates the day of specimen collection from the transplantation event as the 
reference day (Day 0); the y-axis indicates the relative bacterial percentage 
corresponding to each taxon. Each taxon is labeled by color as defined in the 
legend. Panels B and C show the differences in gut microbial composition 
between the pre-transplantation specimens and the 2 week post-transplantation 
specimens by phylum and order levels, respectively. Each color in the pie chart 
represents the corresponding taxon group in the legend. At the phylum level, the 
relative abundance of Proteobacteria (red) was higher in the post-transplantation 
specimens compared to pre-transplantation specimen in all 5 patients (P=0.04, 
Wilcoxon signed-rank test). At the order level, the relative abundance of 
Erysipelotrichales (light blue, P=0.04) and Enterobacteriales (red, P=0.04) were 
higher in the post-transplantation specimen compared to pre-transplantation 
specimen in all 5 patients. From Lee et al., Gut microbial community structure 
and complications after kidney transplantation: a pilot study. Transplantation 
98(7): 697-705. Lippincott Williams & Wilkins. Copyright © 2014. Reprinted with 
permission.  
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Table 2. Alternations in the Gut Microbiota Following Kidney 
Transplantation1 
1 Pre-transplantation fecal specimens (PreTx, N=5 specimens from 5 patients) 
were collected a median of 0 days prior to transplantation and the post 
transplantation samples (PostTx, N=5 specimens) were collected from the same 
5 patient a median of 13 days post transplantation. The relative mean bacterial 
abundance in the PreTx samples and the PostTx samples are shown. P values 
were calculated using a Wilcoxon signed-rank test.  
       
Phylum  PreTx  Post Tx  P value 
  Cohort  Cohort   
   N=5  N=5    
Firmicutes  91.8%  87.7%  0.22 
Actinobacteria  2.0%  7.6%  0.50 
Proteobacteria  0.9%  4.1%  0.04 
Bacteroidetes  2.8%  0.6%  0.08 
       
       
Order  PreTx  Post Tx  P value 
  Cohort  Cohort   
   N=5  N=5    
Clostridiales  64.8%  64.3%  0.69 
Lactobacillales  19.1%  12.0%  0.22 
Erysipelotrichales  5.6%  10.2%  0.04 
Bifidobacteriales  1.6%  6.6%  0.89 
Enterobacteriales  0.4%  3.9%  0.04 
Bacteroidales  2.8%  0.6%  0.08 
     
 
 
From Lee et al., Gut microbial community structure and complications after 
kidney transplantation: a pilot study. Transplantation 98(7): 697-705. Lippincott 
Williams & Wilkins. Copyright © 2014. Reprinted with permission. 
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Shannon diversity index is a measure of alpha diversity in microbial ecology and 
reflects richness (number of different species in an environment) and evenness 
(relative abundance of each species in the environment) [34]. The Shannon 
diversity index was 3.7±0.3 (mean±SD) in the pre-transplantation specimens 
compared to 3.1±0.8 (mean±SD) in the post-transplantation specimens (P=0.22, 
Wilcoxon signed-rank test). 
 
Gut Microbiota and Post-Transplant Diarrhea 
 
 
In order to decrease confounding by induction therapy or antibiotic use, we 
evaluated the 15 kidney transplant recipients who underwent the same induction 
therapy (anti-thymocyte globulin therapy), the same preoperative surgical 
prophylaxis (cefazolin), and the same Pneumocystis jirovecii prophylaxis 
(trimethoprim-sulfamethoxazole). 6 of the 15 kidney transplant recipients 
developed diarrhea with a median duration of diarrhea of 4.5 days and a median 
number of bowel movements of 4 while 9 of the 15 kidney transplant recipients 
did not develop post-transplant diarrhea within the first 3 months of 
transplantation.  
 
We compared the gut microbial composition in the 6 fecal specimens of the 6 
kidney transplant recipients at the time of diarrhea to the gut microbial 
composition in 9 time-matched fecal specimens from the 9 kidney transplant 
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recipients who did not develop diarrhea. Diversity in the diarrhea fecal specimens 
was lower than that in the time-matched no-diarrhea fecal specimens (2.5±0.3 
vs. 3.4±0.8, respectively, P=0.02, Wilcoxon rank-sum test). Principal coordinate 
analysis also showed separation between the diarrhea cohort and no diarrhea 
cohort (Figure 2A). Principal coordinate analysis is based on the dissimilarity 
between two groups using a distant matrix and allows for a representation in two-
dimension space [32]. 
 
Figure 2. Differential Gut Microbial Composition in Patients with or without 
Post-Transplant Diarrhea. Panel A shows the principal coordinate analyses of 
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the 6 patients with diarrhea and the 9 patients without diarrhea. The first two 
axes of the principal coordinate analysis are represented with principal 
coordinate axis 1 on the y-axis (10.60% variability) and principal coordinate axis 
2 on the x-axis (9.17% variability). The individual red points represent the 6 fecal 
specimens from the 6 patients with diarrhea and the individual green points 
represent the 9 fecal specimens from the 9 patients without diarrhea. Panels B 
and C represent the differences in gut microbiota between the diarrhea cohort 
and no diarrhea cohort by phylum and order levels, respectively. Each color in 
the pie chart represents the corresponding taxon group in the legend. 
Bacteroidetes and Bacteroidales are represented in yellow and were significantly 
decreased in the diarrhea cohort (P=0.007, P=0.007, respectively). LEfSe 
method was performed to determine individual taxons that were significantly 
associated with the diarrhea cohort (red) and the no diarrhea cohort (green) 
(Panel D). A cladogram based on the LEfSe method is shown in Panel E and 
highlights the taxonomic groups in the diarrhea cohort (red) and in the no 
diarrhea cohort (green). From Lee et al., Gut microbial community structure and 
complications after kidney transplantation: a pilot study. Transplantation 98(7): 
697-705. Lippincott Williams & Wilkins. Copyright © 2014. Reprinted with 
permission. 
 
We also evaluated the differences in gut microbiota between diarrhea-associated 
fecal specimens and the no diarrhea time-matched fecal specimens at the 
phylum and order level. At the phylum level, fecal abundance of Bacteroidetes 
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was significantly lower in the diarrhea cohort than in the no diarrhea cohort 
(P=0.007) (Figure 2B). At the order level, fecal abundance of Bacteroidales was 
significantly lower in the diarrhea cohort than in the no diarrhea cohort (P=0.007) 
(Figure 2C) (Table 3). 
Table 3. Microbial Composition of Fecal Specimens From the Patients with 
or without Diarrhea, by Phylum and Order1 
1 The relative mean bacterial abundance in the fecal specimens from the 15 
patients who either developed post-transplant diarrhea (Diarrhea Cohort, N = 6 
patients) or did not develop post-transplant diarrhea (No Diarrhea Cohort, N = 9). 
The timing of collection of specimens from the no diarrhea group was matched 
closely to the day of collection following transplantation in the diarrhea group. P 
values were calculated using the Wilcoxon rank-sum test.  
Phylum 
Diarrhea 
Cohort 
No Diarrhea
Cohort   P value 
   N=6  N=9    
Firmicutes  87.2%  91.5%  0.56 
Actinobacteria  11.1%  3.2%  0.60 
Proteobacteria  1.2%  1.3%  0.44 
Bacteroidetes  0.3%  3.4%  0.007 
       
Order  Diarrhea  No Diarrhea  P value 
  Cohort  Cohort   
   N=6  N=9    
Clostridiales  48.4%  66.5%  0.24 
Lactobacillales  19.0%  10.1%  0.64 
Erysipelotrichales  16.4%  13.2%  0.56 
Bifidobacteriales  10.4%  2.6%  0.77 
Enterobacteriales  0.2%  1.1%  0.12 
Bacteroidales  0.3%  3.4%  0.007 
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From Lee et al., Gut microbial community structure and complications after 
kidney transplantation: a pilot study. Transplantation 98(7): 697-705. Lippincott 
Williams & Wilkins. Copyright © 2014. Reprinted with permission. 
 
 
Linear discriminant analysis effect size (LEfSe) method showed significant 
differences between taxa in the diarrhea cohort and taxa in the no diarrhea 
cohort. The LEfSe method allows for biomarker discovery in gut microbiota and 
uses Kruskal-Wallis statistical testing to compare all taxa at different taxonomic 
levels [33]. The LEfSe analysis showed that Bacteroidetes, Bacteroides, 
Ruminococcus, Coprocooccus, and Dorea were significantly lower in the diarrhea 
cohort (Figure 2D). A cladogram of the LEfSe analysis is represented in Figure 
2E. 
 
Gut Microbiota and Enterococcus Urinary Tract Infections 
 
In the series of 26 kidney transplant recipients, 3 recipients developed 
Enterococcus urinary tract infections and 23 did not within the first 3 months of 
transplantation. Patient 2 developed detectable fecal Enterococcus 16 days prior 
to diagnosis of Enterococcus UTI; patient 18 had detectable fecal Enterococcus 
a day after the diagnosis of Enterococcus UTI; patient 26 had detectable 
Enterococcus 39 days after the diagnosis of Enterococcus UTI and 26 days prior 
to the diagnosis of a recurrent Enterococcus UTI. Figure 3 shows the fecal 
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microbiota over time in the 3 transplant recipients with Enterococcus UTI and 3 
representative transplant recipients without Enterococcus UTI and shows that 
fecal Enterococcus abundance precedes and/or coincides with development of 
Enterococcus UTI.  
 
Figure 3. Enterococcus Fecal Abundance and Enterococcus Urinary Tract 
Infections in Allograft Recipients. The 6 sets of bar graphs represent 6 of the 
26 kidney transplant recipients studied; patients 2, 18, and 26 developed 
Enterococcus UTI and patients 9, 12, and 19 are 3 of the 23 patients who did not 
develop Enterococcus UTI. Each bar represents the relative composition of 
bacteria in the stool sample from each patient. The x-axis indicates the day of 
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specimen collection from the transplantation event as the day of reference (day 
0); the y-axis indicates the relative bacterial percentage corresponding to each 
taxon. Each taxon is labeled by color as defined in the legend. Enterococcus 
relative abundance is represented in green and is present in patients 2, 18, and 
26 whereas absent in the patients without Enterococcus UTI. The timing/day of 
the Enterococcus UTI is indicated by the horizontal bar in green above the bar 
graphs. From Lee et al., Gut microbial community structure and complications 
after kidney transplantation: a pilot study. Transplantation 98(7): 697-705. 
Lippincott Williams & Wilkins. Copyright © 2014. Reprinted with permission. 
 
We also compared the Enterococcus abundance in the fecal specimens from the 
3 kidney transplant recipients who developed Enterococcus UTI (Enterococcus 
UTI group) with that in the time-matched fecal specimens from the 23 kidney 
transplant recipients who did not develop Enterococcus UTI (No Enterococcus 
UTI group). The median Enterococcus abundance was 24% in the Enterococcus 
UTI group and 0% in the no Enterococcus UTI group (P=0.005, Wilcoxon rank-
sum test).   
 
Gut Microbiota and Acute Rejection 
 
The same 3 transplant recipients who developed Enterococcus UTI also 
developed acute rejection while the 23 other transplant recipients did not develop 
acute rejection within the first 3 months of transplantation. Patient 2 
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(simultaneous kidney and pancreas transplant recipient) had a biopsy proven 
acute cellular and antibody mediated rejection on post-transplant day 23; patient 
18 (kidney alone transplant recipient) had a biopsy proven antibody mediated 
rejection on post-transplant day 7; and patient 26 (kidney alone transplant 
recipients) had a biopsy proven acute cellular rejection on post-transplant day 64.  
 
The gut microbial composition in the 3 fecal specimens associated with the 3 AR 
events was compared to that in 23 time-matched fecal specimens from the 23 
recipients who did not develop AR. Principal coordinate analysis revealed a 
separation between the AR cohort and no AR cohort (Figure 4A). We also 
compared the gut microbial composition at the phylum level and at the order 
level. At the phylum level, the AR cohort had a lower fecal abundance of 
Bacteroidetes than the no AR cohort (0.02% vs. 3.1%, respectively, P=0.03, 
Wilcoxon rank-sum test). At the order level, the AR cohort had a lower fecal 
abundance of Clostridiales and Bacteroidales than the no AR cohort 
(Clostridiales: 16.9% vs. 63.1%, respectively, P=0.01) (Bacteroidales: 0.02% vs. 
3.1%, P=0.03) (Figure 4B) while AR cohort had a higher fecal abundance of 
Lactobacillales than in the no AR Cohort (49.9% vs. 12.7%, P=0.04) (Figure 4C) 
(Table 4).  
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Figure 4. Differential Gut Microbial Composition in Patients with or without 
Acute Rejection. Panel A represents the principal coordinate analyses of the 
individual patients with or without biopsy confirmed acute rejection. The first two 
axes of the principal coordinate analysis are represented with principal 
coordinate axis 1 on the y-axis (8.17% variability) and principal coordinate axis 2 
on the x-axis (5.58% variability). The individual red points represent the 3 fecal 
specimens from the 3 patients with biopsy confirmed AR and the individual green 
points represent the 23 time matched fecal specimens from the 23 patients who 
27 
           
did not develop AR. Panels B and C represent the differences in fecal microbiota 
between the two groups by phylum and order levels, respectively. Each color in 
the pie chart represents the corresponding taxon in the legend. At the phylum 
level, Bacteroidetes was lower in the AR cohort than in the no AR cohort 
(P=0.03). At the order level, Lactobacillales was higher in the AR cohort (P=0.04) 
and Clostridiales and Bacteroidales was lower in the AR cohort (P=0.01, P=0.03, 
respectively) when compared to the no AR cohort. LEfSe method was performed 
to determine individual taxons that were significantly associated in the AR cohort 
(red) and in the no AR cohort (green) (Panel D). A cladogram based on the 
LEfSe method is shown on Panel E and highlights the taxonomic groups 
associated with AR (red) and no AR (green). From Lee et al., Gut microbial 
community structure and complications after kidney transplantation: a pilot study. 
Transplantation 98(7): 697-705. Lippincott Williams & Wilkins. Copyright © 2014. 
Reprinted with permission 
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Table 4. Microbial Composition of Fecal Specimens From the Patients With 
or Without Acute Rejection, by Phylum and Order1 
1 The relative mean bacterial abundance in the fecal specimens from the 26 
patients who either developed biopsy confirmed acute rejection (AR Cohort, N=3 
patients) or did not develop acute rejection (No AR Cohort, N=23). The timing of 
collection of specimens from the AR group was matched closely to the day of 
collection following transplantation in the no AR group. P values were calculated 
using the Wilcoxon rank-sum test.  
       
Phylum  No AR Cohort  AR Cohort  P value 
       
   N=23  N=3   
Firmicutes  91.4%  76.6%  0.40 
Actinobacteria  3.7%  8.2%  0.60 
Proteobacteria  1.3%  15.2%  0.33 
Bacteroidetes  3.1%  .02%  0.03 
       
       
Order  No AR Cohort  AR Cohort  P value 
   N=23  N=3   
Clostridiales  63.1%  16.9%  0.01 
Lactobacillales  12.7%  49.9%  0.04 
Erysipelotrichales  13.3%  9.2%  0.32 
Bifidobacteriales  3.1%  7.9%  0.44 
Enterobacteriales  1.0%  14.7%  0.17 
Bacteroidales  3.1%  .02%  0.03 
       
From Lee et al., Gut microbial community structure and complications after 
kidney transplantation: a pilot study. Transplantation 98(7): 697-705. Lippincott 
Williams & Wilkins. Copyright © 2014. Reprinted with permission. 
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Using the LEfSe method, we found several significantly different taxa between 
the AR cohort and the no AR cohort. The AR cohort had a higher fecal 
abundance of Lactobacillales, Anaerofilum, Enterococcus, and Clostridium 
tertium and had a lower fecal abundance of Bacteroidales, Clostridiales, 
Lachnospiraceae, Blautia, Ruminococcus, Bacteroides, and Eubacterium 
dolichum (Figure 4D).  The relationships between the significantly different taxa 
is represented in a cladogram in Figure 4E.  
 
In terms of antibiotic use in the AR Cohort, it is important to note that the three 
patients who developed AR had received several multiple antibiotics prior to the 
occurrence of AR. Patient 2 received metronidazole, ceftriaxone, 
piperacillin/tazobactam, and trimethoprim/sulfamethoxazole prior to the diagnosis 
of AR; Patient 18 received flagyl prior to the diagnosis of AR; Patient 26 received 
piperacillin/tazobactam, cefazolin, cephalexin, vancomycin, daptomycin, and 
linezolid prior to the diagnosis of AR. 
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CHAPTER 4 
Gut Microbiota and Tacrolimus Dosing Requirements4 
 
Study Cohort 
We analyzed 19 of the 26 kidney transplant recipients in our pilot study. We 
evaluated this subset of the patients because all 19 patients had the following 
criteria: 1) were kidney alone transplant recipients 2) were maintained on 
tacrolimus maintenance therapy 3) had a fecal specimen within the first week 
post transplantation 4) did not develop acute rejection within the first month of 
transplantation. In terms of interactions with tacrolimus, all 19 kidney transplant 
recipients received clotrimazole twice daily during the first month of 
transplantation; 2 of the 19 transplant recipients were on diltiazem. No other 
patient received strong CYP3A4 inhibitors during the first month of 
transplantation.  
 
Tacrolimus Dosing Groups 
Among the 19 recipients, 5 patients required a 50% increase from standard initial 
tacrolimus dosing (Dose Escalation Group) (tacrolimus dosing > 6 mg/day by the 
end of the first post-transplant month) and 14 patients did not require a 50% 
increase from initial standard tacrolimus dosing (Dose Stable Group) (tacrolimus 
dosing ≤6 mg/day by the end of the first post-transplant month). We compared 
                                                            
4 Adapted with permission from 1) Lee et al., Gut microbial community structure and 
complications after kidney transplantation: a pilot study. Transplantation 98(7): 697‐705. 
Lippincott Williams & Wilkins. Copyright © 2014 and 2) Lee et al., Gut Microbiota and Tacrolimus 
Dosing in Kidney Transplantation. PLOS ONE 10(3):e0122399. Copyright © 2015.   
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clinical and transplant characteristics between the Dose Escalation Group and 
the Dose Stable Group and we did not find significantly different characteristics 
that could affect tacrolimus dosing such as age, gender, weight, race, type of 
transplantation, and steroid maintenance therapy (Table 5). 
 
Table 5. Clinical Characteristics of the Transplant Cohort. 
1 Categorical variables were compared using Fisher’s exact test and continuous 
variables were compared using the Wilcoxon Rank-Sum test. 
Characteristics Dose Escalation Dose Stable 
P 
value1 
  Group (N=5) Group (N=14)   
    
Age (Mean±SD) 43.4±19.0 58.8±7.8 0.16 
Weight (Mean±SD) 81.2±13.6 74.1±14.1 0.23 
Male Gender 4 (80.0%) 4 (28.6%) 0.11 
African American Race 0 (0.0%) 3 (21.4%) 0.53 
Deceased Donor 
Transplantation 2 (40.0%) 6 (42.9%) 0.99 
    
Induction Therapy    
     Anti-thymocyte globulin 5 (100.0%) 11 (78.6%) 0.53 
     Basiliximab  0 (0.0%) 3 (21.4%) 0.53 
Maintenance Therapy    
     Tacrolimus and 
Mycophenolate 5 (100.0%) 14 (100.0%) 0.99 
     Steroid Maintenance 
Protocol 1 (20.0%) 6 (42.9%) 0.60 
Prophylaxis Therapy    
     Preoperative Antibiotic 
Prophylaxis    
        Cefazolin 5 (100.0%) 11 (78.6%)     0.53 
        Vancomycin 0 (0.0%) 3 (21.4%)     0.53 
     Clotrimazole 5 (100.0%) 14 (100.0%)     0.99 
     CMV Prophylaxis    
        Valgancyclovir 4 (80.0%) 13 (92.9%)     0.47 
        Acyclovir 1 (20.0%) 1 (7.1%)     0.47 
     PCP Prophylaxis    
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Trimethoprim/Sulfamethoxazole 5 (100.0%) 11 (78.6%)     0.53 
        Dapsone or Atovaquone 0 (0.0%) 3 (21.4%)     0.53 
    
 
From Lee et al., Gut Microbiota and Tacrolimus Dosing in Kidney 
Transplantation. PLOS ONE 10(3):e0122399. Copyright © 2015. Reprinted with 
permission.    
 
Tacrolimus dosing increased in the Dose Escalation Group when compared to 
the Dose Stable Group during the first month of transplantation, which is in 
response to lower tacrolimus troughs in the Dose Escalation Group than in the 
Dose Stable Group. Figure 5 shows the tacrolimus trough levels and tacrolimus 
dosing in intervals of 7 days during the first month of transplantation, stratified by 
the Dose Escalation Group and in the Dose Stable Group. The Dose Escalation 
Group had initially lower tacrolimus trough levels than the Dose Stable Group 
(4.4±2.6 ng/mL vs. 9.7±3.2 ng/mL, respectively) (P<0.001 at day 7, two-way 
between-group ANOVA using contrasts) but by post-transplant day 28, the Dose 
Escalation Group and the Dose Stable Group had similar tacrolimus trough 
levels) (7.3±2.2 ng/mL and 9.0±2.1 ng/mL, respectively) (P=0.22) (Figure 5A). In 
terms of tacrolimus dosing, the Dose Escalation Group had similar initial 
tacrolimus dosing to the Dose Stable Group (4.2±1.1 mg/day vs. 3.8±0.8 mg/day, 
respectively) (P=0.61, two-way between-group ANOVA using contrasts), but by 
post-transplant day 28, the Dose Escalation Group had a higher tacrolimus 
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dosing than the Dose Stable Group (9.6±2.4 mg/day vs. 3.3±1.5 mg/day, 
respectively) (P<0.001) (Figure 5B).  
  
Figure 5. Tacrolimus Trough Levels and Tacrolimus Dosing in the Kidney 
Transplant Cohort. A) Tacrolimus troughs are shown over the course of the first 
month. On the x-axis is the day after kidney transplantation and on the y-axis is 
the mean tacrolimus trough of the group (ng/mL) corresponding to the day on the 
x-axis. The Dose Escalation Group is represented by the red line with 
corresponding standard deviation bars and the Dose Stable Group is 
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represented by the green line with corresponding standard deviation bars. P 
values at each time point were calculated using a two-way between-group 
ANOVA using contrasts to evaluate the two groups at each time point and is 
listed above each time point. B) Tacrolimus dosing is shown over the course of 
the first month. On the x-axis is the day after kidney transplantation and on the y-
axis is the mean tacrolimus dosing of the group (mg/day) corresponding to the 
day on the x-axis. The Dose Escalation Group is represented by the red line with 
corresponding standard deviation bars and the Dose Stable Group is 
represented by the green line with corresponding standard deviation bars. P 
values at each time point were calculated using a two-way between-group 
ANOVA using contrasts to evaluate the two groups at each time point and is 
listed above each time point.  
From Lee et al., Gut Microbiota and Tacrolimus Dosing in Kidney 
Transplantation. PLOS ONE 10(3):e0122399. Copyright © 2015. Reprinted with 
permission.   
 
Gut Microbiota Early After Transplantation by Tacrolimus Dosing Groups 
 
We evaluated whether the gut microbiota within the first week after kidney 
transplantation (N=19 fecal specimens) was associated with tacrolimus dosing 
groups by diversity assessment and by principal coordinate analysis. The 
Shannon diversity index in the Dose Escalation Group (N=5) was not significantly 
that that in the Dose Stable Group (N=14) (3.5±0.8 vs. 3.5±0.5, respectively, 
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P=0.78, Wilcoxon Rank Sum test). With respect to principal coordinate analysis, 
the gut microbiota in the Dose Escalation Group and the Dose Stable Group did 
not appear to have a separation (Figure 6). 
 
Figure 6. Differences in the Gut Microbiota Between the Tacrolimus 
Groups. The principal coordinate analyses of the week 1 fecal specimens from 
the 19 kidney graft recipients are shown. The first two axes of the principal 
coordinate analysis are represented with principal coordinate axis 1 on the y-axis 
(10.7% variability) and principal coordinate axis 2 on the x-axis (7.2% variability). 
The individual red points represent the 5 post-transplantation week 1 fecal 
specimens from the 5 subjects in the Dose Escalation Group and the individual 
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green points represent the 14 post-transplantation week 1 fecal specimens from 
the 14 subjects in the Dose Stable Group. 
From Lee et al., Gut Microbiota and Tacrolimus Dosing in Kidney 
Transplantation. PLOS ONE 10(3):e0122399. Copyright © 2015. Reprinted with 
permission.  
 
In the same week 1 post-transplant fecal specimens (N=19), we evaluated 
whether there was a significantly different taxa at the phylum, order, genus, and 
species (evaluation of taxa >2% within each level) between the two tacrolimus 
groups (Table 6). At the genus level, the Dose Escalation Group had a 
significantly higher fecal Faecalibacterium abundance than the Dose Stable 
Group (11.8% vs. 0.8%, P=0.002, Wilcoxon rank sum test) at week 1 post-
transplant. At the species level, the Dose Escalation group had a significantly 
higher fecal Faecalibacterium prausnitzii abundance than the Dose Stable Group 
(11.8% vs. 0.8%, P=0.002, Wilcoxon rank sum test) at week 1 post-transplant. 
The fecal abundance of Faecalibacterium prausnitzii in the 19 kidney transplant 
recipients is represented on Figure 7. 
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Table 6: Comparison of the Most Common Taxa Between the Tacrolimus 
Groups 
At each of the most common taxa at the phylum, order, genus, and species 
levels, the mean bacterial abundances in the post-transplantation week 1 fecal 
specimens from the 5 transplant recipients in the Dose Escalation Group were 
compared to the mean bacterial abundances in those from the 14 transplant 
recipients in the Dose Stable Group. Unadjusted p values were calculated using 
Wilcoxon rank sum tests and the adjusted p values were calculated using the 
Benjamini-Hochberg correction for multiple hypotheses at each taxonomic level. 
Fecal Faecalibacterium prausnitzii abundance at week 1 post-transplantation 
was significantly higher in the Dose Escalation Group than in the Dose Stable 
Group (mean 11.8% vs. 0.8%, respectively, uncorrected P=0.002, Wilcoxon rank 
sum test, P<0.05 after Benjamini-Hochberg correction for multiple hypotheses).  
 
Phylum 
Dose Escalation 
Group (N=5) 
Dose Stable 
Group (N=14) 
P value  
 
Firmicutes 0.866 0.906 0.89 
Actinobacteria 0.039 0.036 0.96 
Bacteroidetes 0.016 0.021 0.52 
       
Order     
Clostridiales 0.611 0.610 0.99 
Erysipelotrichales 0.173 0.165 0.89 
Lactobacillales 0.012 0.087 0.71 
Bifidobacteriales 0.036 0.032 0.71 
Bacteroidales 0.016 0.021 0.52 
       
Genus     
Clostridium 0.103 0.187 0.11 
Eubacterium 0.149 0.137 0.82 
Blautia 0.065 0.062 0.82 
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Faecalibacterium 0.118 0.008 0.002 
Streptococcus 0.010 0.064 0.85 
Ruminococcus 1 0.032 0.042 0.56 
Ruminococcus 2 0.147 0.085 0.30 
Bifidobacterium 0.036 0.032 0.71 
Coprococcus 0.025 0.040 0.61 
unclassified Clostridiales 0.022 0.034 0.49 
       
Species     
Eubacterium dolichum 0.149 0.121 0.99 
unclassified Clostridium 0.057 0.090 0.69 
Faecalibacterium 
prausnitzii 0.118 0.008 0.002 
Blautia producta 0.016 0.020 0.43 
unclassified Blautia 0.016 0.032 0.75 
Bifidobacterium breve 0.019 0.009 0.34 
Streptococcus 
thermophilus 0.008 0.025 0.89 
Ruminococcus bromii 0.103 0.042 0.14 
Ruminococcus gnavus 0.011 0.012 0.96 
unclassified Coprococcus 0.020 0.038 0.46 
unclassified 
Ruminococcus 0.043 0.043 0.96 
Streptococcus lutetiensis 0.0001 0.030 0.49 
unclassified Clostridiales 0.022 0.034 0.49 
 
From Lee et al., Gut Microbiota and Tacrolimus Dosing in Kidney 
Transplantation. PLOS ONE 10(3):e0122399. Copyright © 2015. Reprinted with 
permission 
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Figure 7. Fecal Faecalibacterium prausnitzii Abundance by Tacrolimus 
Dosing Groups. Each individual subject is represented on the x-axis and the 
week 1 fecal Faecalibacterium prausnitzii abundance is represented on the y-
axis. Individual subjects in the Dose Stable Group are represented in green (the 
14 subjects on the left) and individuals subjects in the Dose Escalation Group are 
represented in red (the 5 subjects on the right). The Dose Escalation Group had 
a significantly higher Faecalibacterium prausnitzii proportion than the Dose 
Stable Group (11.8% vs. 0.8%, P=0.002, Wilcoxon Rank-Sum test). 
From Lee et al., Gut Microbiota and Tacrolimus Dosing in Kidney 
Transplantation. PLOS ONE 10(3):e0122399. Copyright © 2015. Reprinted with 
permission.  
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14 of the 19 transplant recipients had available fecal specimens for microbial 
profiling at or after day 14 of transplantation. The fecal abundance of 
Faecalibacterium prausnitzii continued to be elevated in the Dose Escalation 
Group than in the Dose Stable Group (20.0% vs. 5.5%, respectively, P=0.07, 
Wilcoxon Rank Sum test) but this was only a trend towards significance. 
 
Faecalibacterium prausnitzii’s Correlation with Tacrolimus Dosing 
 
We evaluated whether there was a linear relationship between the post-
transplant week 1 fecal Faecalibacterium prausntizii abundance and tacrolimus 
dosing at 1 month. In this univariate linear regression with log-transformed 
Faecalibacterium prausnitzii abundance at 1 week post-transplantation, we found 
a significant coefficient±SE (1.7±0.6, P=0.01). We also evaluated whether 
several other transplant characteristics were associated with tacrolimus dosing. 
We also found that Age and Week 1 hemoglobin concentrations were associated 
with 1 month tacrolimus dosing (Table 7) (Age: Coefficent±SE -0.14±0.05, 
P=0.02; Hemoglobin: Coefficent±SE -1.4±0.6, P=0.03). The correlations of the 
log-transformed week 1 fecal Faecalibacterium prausnitzii abundance and 1 
month tacrolimus dosing, of Age and 1 month tacrolimus dosing, and week 1 
hemoglobin concentration and 1 month tacrolimus dosing are represented in 
Figure 8. 
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Table 7: Characteristics Associated with Tacrolimus Dosing at 1 Month 
Linear regressions were performed for each of the listed characteristics and the 
coefficient, standard error (SE), and P values are listed. Characteristics that were 
associated with tacrolimus dosing at 1 month (P value < 0.10) were computed in 
a multivariable linear regression and the coefficient, SE, and P values are listed 
for each of these characteristics. 
 
1 ALT: Alanine aminotransferase 
2 Hgb: hemoglobin 
3 Post Tx: post-transplantation 
 
 Univariate Analysis Multivariable Analysis 
             
Characteristic 
Coefficie
nt SE 
P-
valu
e 
Coefficie
nt SE 
P-
valu
e 
Age (years) (continuous) -0.14 
0.0
5 0.02 -0.09 
0.0
5 0.07 
Transplant Weight (kg) 
(continuous) 0.05 
0.0
6 0.37    
Male Gender (dichotomous) 2.5 1.5 0.11    
African American 
(dichotomous) -1.5 2.1 0.49    
Deceased Donor Transplant 
(dichotomous) 0.14 1.6 0.93    
Steroid Maintenance 
(dichotomous) -2.0 1.6 0.21    
Baseline ALT1 (IU/L) 
(continuous) 0.03 
0.0
9 0.77    
Baseline Albumin (mg/dL) 
(continuous) 0.5 1.5 0.76    
Hgb2 1 Week Post Tx3 
(mg/dL) (continuous) -1.4 0.6 0.03 -0.9 0.5 0.10 
Log F.Prausnitzii 1 Week 
Post Tx3 (continuous) 1.7 0.6 0.01 1.0 0.6 0.08 
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From Lee et al., Gut Microbiota and Tacrolimus Dosing in Kidney 
Transplantation. PLOS ONE 10(3):e0122399. Copyright © 2015. Reprinted with 
permission. 
 
 
Figure 8. Correlations with Tacrolimus Dosing at 1 Month. A) Fecal 
Faecalibacterium prausnitzii abundance at 1 week post-transplantation is 
associated with tacrolimus dosing at 1 month. On the x-axis is the log 
transformed fecal week 1 Faecalibacterium prausnitzii abundance and on the y-
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axis is the corresponding subject’s tacrolimus dosing at 1 month (mg/day). There 
was a positive correlation between the log-transformed fecal week 1 
Faecalibacterium prausnitzii abundance and tacrolimus dosing at 1 month 
(Pearson R=0.57, P=0.01). B) Age at transplantation is negatively associated 
with tacrolimus dosing at 1 month. On the x-axis is the age at transplantation and 
on the y-axis is the corresponding subject’s tacrolimus dosing at 1 month 
(mg/day). There was a negative correlation between age and tacrolimus dosing 
at 1 month (Pearson R=-0.55, P=0.02). C) Post-transplantation week 1 
hemoglobin concentration is negatively associated with tacrolimus dosing at 1 
month. On the x-axis is the week 1 hemoglobin concentration and on the y-axis is 
the corresponding subject’s tacrolimus dosing at 1 month (mg/day). There was a 
negative correlation between week 1 hemoglobin concentration and tacrolimus 
dosing at 1 month (Pearson R=-0.50, P=0.03). 
From Lee et al., Gut Microbiota and Tacrolimus Dosing in Kidney 
Transplantation. PLOS ONE 10(3):e0122399. Copyright © 2015. Reprinted with 
permission.   
 
With factors associated with a P <0.10 in univariate linear regression, we 
performed a multivariable linear regression for 1 month tacrolimus dosing as the 
dependent variable. There continued to be a trend towards significance that the 
fecal Faecalibacterium prausnitzii abundance at week 1 post-transplantation was 
significantly correlated with future 1 month tacrolimus dosing (Coefficient±SE, 
1.0±0.6, P=0.08) (Table 7). 
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CHAPTER 5 
Discussion and Implications5 
 
In this pilot study, we describe one of the first characterization of the changes in 
the gut microbiota after kidney transplantation and the relationship between the 
gut microbiota and the following post-transplant complications: diarrhea, 
Enterococcus urinary tract infections, and acute rejection. We also describe, for 
the first time, an association between the gut microbiota and tacrolimus dosing 
requirements in kidney transplantation.  
 
Little is known about the changes in the gut microbiota after kidney 
transplantation. Kidney transplantation involves high dose immunosuppressive 
therapies and preoperative and prophylactic antibiotics and such therapies have 
unknown effects on the gut microbiota. In a cynomolgus monkey study, the 
effects of alemtuzumab were examined on the gut microbiota and the study 
revealed profound changes in the Lactobacillales, Enterobacteriales, and 
Clostridiales [35]. In a study of the rectal microbiota after kidney transplantation, 
Fricke et al. evaluated 60 kidney transplant recipients and described significant 
changes in various genera from the Firmicutes phylum from pre-transplantation 
to one month post-transplantation [21]. In the current study, we report a 
significant increase in the fecal Proteobacteria two weeks post kidney 
                                                            
5 Adapted with permission from 1) Lee et al., Gut microbial community structure and 
complications after kidney transplantation: a pilot study. Transplantation 98(7): 697‐705. 
Lippincott Williams & Wilkins. Copyright © 2014 and 2) Lee et al., Gut Microbiota and Tacrolimus 
Dosing in Kidney Transplantation. PLOS ONE 10(3):e0122399. Copyright © 2015.   
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transplantation. Proteobacteria encompasses a group of gram negative bacteria 
that are known to cause pathogenic infections [36]. A recent study by Taur et al. 
revealed that Proteobacteria domination in the gut (as defined by 30% relative 
abundance) was associated with a 5 fold increase risk of Proteobacteria 
bacteremia [8]. While this study did not assess a similar type of risk, an increase 
in fecal Proteobacteria abundance may provide a potential explanation for the 
increased rate of infectious bacterial complications in kidney transplant 
recipients.  
 
We also describe an association between the gut microbiota and post-transplant 
diarrhea in this series of kidney transplant recipients. Diarrhea is a common post-
transplant complication with an incidence of approximately 20% [37] although the 
incidence is probably larger as the Bunnapradist et al. study was retrospective. 
Common strategies to treat the diarrhea include changes in the 
immunosuppressive regimen, particularly decreases in mycophenolate mofetil. 
Studies, however, have shown that reduction in mycophenolate mofetil has been 
associated with acute rejection and graft loss [38, 39]. In this study, we report 
that a lower abundance of Bacteroides, Ruminococcus, Coprococcus, and Dorea 
is associated with post-transplant diarrhea. Bacteroides and Ruminococcus are 
common commensal bacteria found in the gut and are thought to have a role in 
degradation of nondigestible carbohydrates and host carbohydrates [40, 41]. It is 
plausible that a lack of such bacteria or a decrease in such bacteria is associated 
with a gut dysbiosis that leads to diarrhea. While this pilot study did not provide a 
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mechanism, it nevertheless suggests potential gut microbiota-related treatment 
strategies as alternatives to reduction in immunosuppressive therapies like 
mycophenolate mofetil. 
 
Recent studies have suggested that the gut microbiota may play a role in 
infectious bacterial complications beyond Clostridium difficile. In a study by 
Ubeda et al., Enterococccus abundance in the stool preceded development of 
Enterococcus bacteremia in 2 allogeneic bone marrow transplant recipients [7]. A 
follow up study of 94 allogeneic bone marrow transplant recipients reported that 
Enterococcus domination in the stool (> 30% relative abundance) was associated 
with a 9 fold increased risk for Enterococcus bacteremia [8]. In the current study, 
we report that Enterococcus abundance in the stool was elevated in the subset of 
kidney transplant recipients that developed Enterococcus UTI. While our study 
needs further validation, it supports the association of the gut microbiota and 
bacterial infectious complications and thus provides the basis for newer therapies 
(e.g. probiotics or fecal transplantation) to decrease the risk and/or treat 
complicated infectious complications. 
 
In this study, we also report a preliminary gut microbial signature associated with 
acute rejection in kidney transplantation. We have found that the gut microbiota 
associated with acute rejection is characterized by a lower abundance of 
Bacteroidetes, Clostridiales, and Bacteroidales and a higher abundance of 
Lactobacillales. Several other studies have also found a gut microbial signature 
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with rejection processes in other organ transplantations. In a study of 19 small 
bowel transplant recipients, an increase in Proteobacteria and a decrease in 
Firmcutes was associated with acute rejection [11]. In a study of 16 allogeneic 
bone marrow transplant recipients, microbial chaos in fecal specimens was 
identified as a risk factor for development of graft-versus-host disease [12]. 
Taken together with the small bowel transplant and allogeneic bone marrow 
transplant studies, our preliminary results suggest the possibility that the gut 
microbiota, which has been attributed to have a role in shaping the immune 
system, may also play a role in shaping transplant immunity. 
 
In addition to the gut microbiota’s association with post-transplant complications, 
we also report a novel association between the gut microbiota and tacrolimus 
dosing requirements in kidney transplantation. Prior studies have examined 
clinical and genetic factors such as race and CYP3A5 polymorphisms as 
associated with tacrolimus dosing requirements [42, 43]. This is, to the best of 
our knowledge, one of the first studies to describe fecal Faecalibacterium 
prausnitzii abundance as associated with tacrolimus dosing requirements. We 
report the fecal abundance of Faecalibacterium prausnitzii at week 1 post-
transplantation is associated with future 1 month tacrolimus dosing requirements. 
Faecalibacterium prausnitzii is a gram positive bacterium that has been reported 
to produce high amounts of butyrate [44, 45]. Butyrate is implicated in the 
maintenance of colonic mucosal health [46] and as such, disease processes like 
inflammatory bowel diseases have been reported to have a decrease in fecal 
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Faecalibacterium prausnitzii abundance [47]. The mechanism by which 
Faecalibacterium prausnitzii affects tacrolimus metabolism is unknown but may 
be postulated to be affecting the health of the intestinal microbiota and thus the 
functions of CYP3A4 and P glycoprotein. While this pilot study needs further 
validation, it does support a role for the gut microbiota in tacrolimus metabolism 
and may allow us to better understand the variability in tacrolimus trough levels in 
the setting of gastrointestinal disturbances like diarrhea. 
 
Several limitations exist in the current study that are important to note. The 
sample size of the pilot study is small and most of the reported statistical 
associations are based on univariate analyses. The findings associated with 
acute rejection and Enterococcus UTI may be confounded by differences in 
antibiotic use. In terms of the association with tacrolimus dosing, we did not 
evaluate CYP3A5 polymorphisms, which is an important known contributor for 
tacrolimus metabolism. We also did not evaluate diet and this may have 
impacted gut microbial composition.  
 
Despite these limitations, our pilot study reports gut microbial signatures 
associated with the post-transplant complications of diarrhea, Enterococcus UTI, 
and acute rejection and with tacrolimus dosing requirements. Our study lays the 
foundation for potential future studies utilizing gut microbiota modulation 
strategies like probiotics to prevent and/or treat post-transplant complications in 
kidney transplantation.   
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